Latest filing published 24 Sept 2026 for Theravance Biopharma, Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Donal O'Connor is a declared insider at 2 companies (board member); the most frequent names are Theravance Biopharma, Inc. and PERRIGO Co plc. In total, 13 filings cover trades dated from 7 May 2021 to 23 September 2026.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
Most recently, on 24 September 2026, the filings show a transaction in Theravance Biopharma, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
13 of 13 declarations